picolinic acid has been researched along with Schizophrenia in 4 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 7.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 5.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 3.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 1.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanchanatawan, B | 2 |
| Maes, M | 2 |
| Zavitsanou, K | 1 |
| Lim, CK | 1 |
| Purves-Tyson, T | 1 |
| Karl, T | 1 |
| Kassiou, M | 1 |
| Banister, SD | 1 |
| Guillemin, GJ | 1 |
| Weickert, CS | 1 |
| Sirivichayakul, S | 1 |
| Ruxrungtham, K | 1 |
| Carvalho, AF | 1 |
| Geffard, M | 1 |
| Ormstad, H | 1 |
| Anderson, G | 1 |
| Hockney, RA | 1 |
| Montgomery, P | 1 |
| Williams, C | 1 |
| Geddes, JR | 1 |
| Cowen, PJ | 1 |
1 trial available for picolinic acid and Schizophrenia
| Article | Year |
|---|---|
Lack of effect of chromium supplementation on mental state and body weight in people with schizophrenia.
Topics: Adult; Affect; Aged; Antipsychotic Agents; Body Weight; Dietary Supplements; Double-Blind Method; Fe | 2006 |
3 other studies available for picolinic acid and Schizophrenia